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Background: Comorbidity is common among patients with myocardial infarction (MI). We
examined whether comorbidity level modified the single-photon emission computed tomo-
graphy myocardial perfusion imaging (SPECT MPI)-based prediction of 5-year risk of MI
and all-cause death in patients with MI.
Methods: This cohort study included patients with prior MI having a SPECT MPI at Aarhus
University Hospital, Denmark, 1999–2011. Using nationwide registries, we obtained infor-
mation on comorbidity levels (low, moderate, and severe) and outcomes. We computed risk
and hazard ratios (HRs) with 95% confidence intervals (CIs) for MI and all-cause death,
comparing normal (no defects) versus abnormal scan (reversible and/or fixed defects) using
Cox regression adjusting for sex, age, and comorbidity level.
Results: We identified 1,192 patients with MI before SPECT MPI. The 5-year risk for
patients with normal versus abnormal scans were 11.7% versus 18.3% for MI, and 8.0%
versus 13.2% for all-cause death, respectively. The overall 5-year adjusted HR (aHR) of MI
was 1.56 (95% CI: 1.09–2.21), 1.33 (95% CI: 0.82–2.15) with low comorbidity, 1.39 (95%
CI: 0.68–2.83) with moderate comorbidity, and 2.53 (95% CI: 1.14–5.62) with severe
comorbidity. Similarly, the 5-year aHR for all-cause death was 1.39 (95% CI: 0.90–2.14)
overall; 2.33 (95% CI: 0.79–6.84) with low comorbidity, 2.05 (95% CI: 0.69–6.06) with
moderate comorbidity, and 1.07 (95% CI: 0.64–1.80) with severe comorbidity.
Conclusion: We conclude that comorbidity level may modify the 5-year risk prediction
associated with an abnormal SPECT MPI scan in patients with previous MI.
Keywords: comorbidity, epidemiology, myocardial infarction, myocardial perfusion imaging
Introduction
Single-photon emission computed tomography myocardial perfusion imaging
(SPECT MPI) is a non-invasive procedure for risk stratification after myocardial
infarction (MI).1,2 With increasing age, the number of patients with chronic dis-
orders are increased.3 Concurrently, life expectancy among MI patients has
increased during recent decades due to improvements in treatment and
rehabilitation.4,5 Consequently, more MI patients have other chronic diseases, i.e
comorbidities.6 The prevalence of comorbidity among MI patients may be
increased further due to shared risk factors between cardiovascular disease and
other diseases, such as diabetes.7
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It has previous been shown that comorbidity level did
not affect substantially the association between SPECT
MPI scan result and the risk of MI and all-cause death in
patients without previous MI or cerebrovascular disease.8
Despite the common presence of comorbid conditions in
MI patients, the impact of comorbidity level on the prog-
nosis following a normal versus abnormal SPECT MPI
scan in MI patients has to our knowledge not previously
been examined. We therefore examined the SPECT MPI-
predicted 5-year risk of MI and all-cause death following a
normal versus abnormal SPECT MPI scan in patients with
previous MI, both overall and according to comorbidity
level.
Methods
Setting
The Danish National Health Service provides free univer-
sal tax-supported healthcare, guaranteeing unfettered
access to general practitioners and hospitals.9 Using the
unique 10-digit Civil Personal Register number assigned
to each individual who was born in or immigrated to
Denmark, it is possible to link all Danish medical regis-
tries at the individual level.10
Study population
We conducted this cohort study in Denmark using the
Aarhus University Hospital Myocardial Perfusion
Imaging (AUH-MPI) Database.8 According to a pre-
viously published paper, this database has collected infor-
mation on all 99mTc-sestamibi SPECT MPI procedures
performed at Aarhus University Hospital, Skejby,
Denmark from January 1999 until April 2011, and con-
tains information on sex, age, and scan result.8 We used
the AUH-MPI Database to identify all adult Danish
patients (over the age of 18 years) who had a 99mTc-
sestamibi SPECT MPI procedure performed between
January 1999 and April 2011. To be eligible for inclusion
in this study, patients should have a first-time MI diagnosis
within 5 years before the SPECT MPI procedure date, as
ascertained from the Danish National Patient Registry
(DNPR). The DNPR has recorded information on patients
discharged from all non-psychiatric hospitals in Denmark
since 1977 and from emergency room and outpatient clinic
visits since 1995.11 One primary diagnosis and up to 19
secondary diagnoses are provided for each hospital dis-
charge or outpatient clinical visit, classified according to
the International Classification of Diseases, 8th Revision
(ICD-8) until the end of 1993 and 10th Revision (ICD-10)
thereafter.11 We considered only the first SPECT MPI
procedure in the study period for each patient.
The SPECT MPI procedure is performed by combining
a stress and a rest scan to evaluate any signs of reversi-
bility, irreversibility, or a combination of both. Stress is
applied either physically on an ergometer bicycle or phar-
macologically with vasodilating (adenosine or dipyrida-
mole) or beta stimulating (dobutamine) drugs. A normal
scan was defined as a scan without defects, and an abnor-
mal scan was defined by the presence of a reversible and/
or fixed defect.8 We further subdivided an abnormal scan
into 3 groups: a reversible defect, a fixed defect, and a
combined defect (reversible and fixed defect).
Outcomes
We used the DNPR11 to identify all inpatient admissions
and outpatient clinic contacts with a primary or secondary
diagnosis of MI following a SPECT MPI procedure during
the study period.
We used the Danish Civil Registration System10 to
obtain information on all-cause mortality. This registry
has recorded information on date of birth, residence, date
of emigration, and exact date of any death for the entire
Danish population since 1968, with daily electronic
updates.10
Comorbidity
We obtained information on comorbid conditions from
inpatient and outpatient hospital diagnoses recorded in
the DNPR11 between 1977 and the date of the SPECT
MPI procedure. The severity of comorbidity was categor-
ized using Charlson Comorbidity Index (CCI) scores.12
CCI scores have been found to be a valid method for
measuring comorbidity,13 also in MI patients.14 We com-
puted the CCI score by summing the weight of the remain-
ing 18 conditions included in the CCI after excluding MI.
We then categorized the study population according to the
following comorbidity levels: score of 0 (low comorbid-
ity), score of 1 (moderate comorbidity), and score ≥2
(severe comorbidity).
Statistical analysis
We used descriptive statistics to characterize the study
population undergoing SPECT MPI according to sex,
age, comorbidity level, and cardiovascular morbidity (con-
gestive heart failure, peripheral vascular disease, cerebro-
vascular disease, and diabetes). Follow-up began on the
Schelde et al Dovepress
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date of the SPECT MPI procedure or discharge from the
hospital admission during which the SPECT MPI proce-
dure was performed. Follow-up continued until the date of
MI, death, emigration, 5 years of follow-up, or November
15, 2013, whichever came first.
We used a cumulative incidence method to calculate the
absolute risk and risk difference of MI and all-cause death
within 30 days (including 0 days and 30 days), 31−365 days
(including 31 days, and excluding 365 days), 1−5 years
(including 1 year, and excluding 5 years), and 5 years over-
all following SPECT MPI, and illustrated graphically the
risk for all-cause death. Death was considered a competing
risk in the analyses of MI.
We assessed the impact of comorbidity on risk of MI and
all-cause death in MI patients following a normal versus
abnormal SPECT MPI scan by stratifying the analyses by
comorbidity level. We used Cox proportional hazards regres-
sion to compute 5-year hazard ratios (HRs) with 95% con-
fidence intervals (CIs) for each outcome, comparing an
abnormal scan with a normal scan, and adjusting for cate-
gories of sex, age (18−49 years, 50−59 years, 60−69 years,
and ≥70 years), and comorbidity level (low, moderate, and
severe comorbidity).
In addition, we conducted 3 sensitivity analyses. The
first analysis restricted the outcome to MI diagnoses
during an acute inpatient admission. The second and
third analyses were restricted to patients diagnosed
with a first-time MI 0–1 year and >1–5 years before
the SPECT MPI procedure, respectively, to examine the
consistency of associations according to time from
infarction. The proportional hazards assumption was
assessed graphically by log(-log)-plots and found valid
within the 0–5-year period. The ICD codes for condi-
tions included in the CCI and for MI are provided in
Table S1 and S2. All statistical analyses were conducted
using Stata software 12.1 (StataCorp LP, College
Station, Texas, USA).
Ethics statement
The study was approved by the Danish Data Protection
Agency (record number 2015-57-0002; Aarhus University
record number 2016-051-000001-509).
Results
Patient characteristics
We identified 1,192 patients with a first-time MI within
5 years before the SPECT MPI. Among these, 362 patients
(30%) had a normal scan and 830 patients (70%) had an
abnormal scan (Table 1). Their sex and age distributions
are shown in Table 1. A total of 152 patients had reversible
scan defects, 403 patients had fixed scan defects, and 275
patients had combined scan defects. Among patients with
a normal scan, 54% had a low comorbidity level, and
among patients with an abnormal scan, 44% had a low
comorbidity level. The prevalence of patients with moder-
ate comorbidity was nearly equally distributed among
patients with normal and abnormal scans (25% versus
26%). Patients with a normal scan were less likely to
have severe comorbidity than patients with an abnormal
scan (21% versus 30%) (Table 1). Patients with a normal
scan also were less likely to have had congestive heart
failure than patients with an abnormal scan (9% versus
21%). The prevalence of peripheral vascular disease was
very similar among patients with normal and abnormal
scans (8% versus 9%) (Table 1). The prevalence of cere-
brovascular disease and diabetes was lower among
patients with a normal scan than among patients with an
abnormal scan (8% versus 12%, and 12% versus 15%,
respectively) (Table 1).
The median time from MI to SPECT MPI within the
study cohort was 0.9 years (interquartile range (IQR): 0.3
years to 2.2 years).
Outcomes
Within 5 years after SPECT MPI, 190 MIs and 131 all-
cause deaths occurred in the cohort (Table 2). Median
follow-up time for all-cause death was 5 years (IQR:
4.6 years to 5 years), and for MI the median follow-up
time was 5 years (IQR: 3.5 years to 5 years).
Five-year risk ofMIwas 11.7% (95%CI: 8.5–15.5) among
patients with normal scans, and 18.3% (95% CI: 15.7–21.0)
among patients with abnormal scans (Table 2). The corre-
sponding adjusted HR (aHR) in the 5-year period was 1.56
(95% CI: 1.09–2.21) (Table 2). The overall 5-year risk differ-
ence is shown in Table 2. Risk estimates within 0–30 days, 31–
365 days, and 1–5 years following SPECTMPI are provided in
Table 3. Sensitivity analyses restricted to the 112MI diagnoses
during an acute admission supported the overall result, with
aHR of 1.35 (95% CI: 0.86–2.12) (Table 4). Using a normal
scan as the reference, the aHR for the 5-year period was 1.22
(95% CI: 0.72–2.07) for a reversible defect, 1.58 (95% CI:
1.07–2.33) for a fixed defect, and 1.72 (95%CI: 1.14–2.61) for
a combined defect (Table 5). The sensitivity analyses that
examined the consistency of associations according to time
from MI to SPECT MPI supported the overall result with an
Dovepress Schelde et al
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aHR of 1.53 (95% CI: 0.95–2.47) for MI patients whose
infarction occurred 0–1 year before SPECT MPI (Table S3),
and 1.57 (95%CI: 0.93–2.65) forMI patients whose infarction
occurred >1–5 years before SPECT MPI (Table S4).
Patients with a normal scan had a 5-year mortality risk of
8.0% (95% CI: 5.5–11.5). In patients with an abnormal scan,
this risk was 13.2% (95% CI: 11.0–15.7) (Table 2). The
corresponding aHR was 1.39 (95% CI: 0.90–2.14) (Table
2). The cumulative mortality risk is provided in Figure 1. The
overall 5-year risk difference is shown in Table 2, and risk
estimates within 0–30 days, 31–365 days, and 1–5 years
following SPECT MPI are provided in Table 3.
Using a normal scan as reference, the aHR was 0.97
(95% CI: 0.51–1.85) for a reversible defect, 1.41 (95%
CI: 0.87–2.27) for a fixed defect, and 1.61 (95% CI:
0.99–2.64) for a combined defect (Table 5). No sub-
stantial differences were seen in the aHRs in sensitivity
analyses restricted to patients whose previous MI
occurred 0–1 year before SPECT MPI (aHR =1.19;
95% CI: 0.65–2.17) (Table S3) or >1–5 years before
SPECT MPI (aHR =1.56; 95% CI: 0.84–2.89) (Table
S4), compared to the overall results.
Comorbidity
For all 3 levels of comorbidity, an abnormal scan was asso-
ciated with an increased 5-year risk of MI compared with a
normal scan, as well as considerable risk differences between
patients with a normal versus abnormal scan (Table 2). Five-
year aHRs comparing an abnormal scan with a normal scan
were 1.33 (95% CI: 0.82–2.15) among patients with low
comorbidity, 1.39 (95% CI: 0.68–2.83) among patients with
moderate comorbidity, and 2.53 (95% CI: 1.14–5.62) among
patients with severe comorbidity (Table 2).
Compared with a normal scan, an abnormal scan was
associated with an increased 5-year risk of all-cause death
among patients with all 3 levels of comorbidity (Table 2).
Risk differences according to comorbidity levels were 3.7%
(95% CI: 0.5–6.8) for low comorbidity, 5.1% (95% CI: -1.5–
11.6) for moderate comorbidity, and 0.8% (95% CI: -10.9–
12.4) for severe comorbidity (Table 2). Comparing an abnor-
mal scan with a normal scan, the 5-year aHR was 2.33 (95%
CI: 0.79–6.84) among patients with low comorbidity, 2.05
(95%CI: 0.69–6.06) among patients with moderate comorbid-
ity, and 1.07 (95% CI: 0.64–1.80) among patients with severe
comorbidity (Table 2).
Table 1 Patients with normal and abnormal scans by sex, age, comorbidity level, and cardiovascular morbidity
Characteristics Normal scan (n=362) Abnormal scan (n=830) Total (n=1,192)
Sex
Female 165 (46%) 233 (28%) 398 (33%)
Male 197 (54%) 597 (72%) 794 (67%)
Age (years)
18−49 69 (19%) 149 (18%) 218 (18%)
50−59 119 (33%) 236 (28%) 355 (30%)
60−69 95 (26%) 245 (30%) 340 (29%)
≥70 79 (22%) 200 (24%) 279 (23%)
Median age (years) 59 60 60
Comorbidity level*
Low 195 (54%) 369 (44%) 564 (47%)
Moderate 89 (25%) 215 (26%) 304 (26%)
Severe 78 (21%) 246 (30%) 324 (27%)
Cardiovascular morbidity
Congestive heart failure 34 (9%) 171 (21%) 205 (17%)
Peripheral vascular disease 30 (8%) 78 (9%) 108 (9%)
Cerebrovascular disease 30 (8%) 97 (12%) 127 (11%)
Diabetes 43 (12%) 126 (15%) 169 (14%)
Note: Included are patients with a first-time myocardial infarction within 5 years before the scan. *Levels of comorbidity were based on Charlson Comorbidity Index scores
as follows: 0 (low), 1 (moderate), and ≥2 (severe).
Schelde et al Dovepress
submit your manuscript | www.dovepress.com
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Discussion
In this cohort study of patients with previous MI, we found
that comorbidity level may modify the 5-year risk predic-
tion of an abnormal SPECT MPI scan for MI and all-cause
death. The impact of an abnormal scan was strongest for
MI in patients with severe comorbidity. For all-cause
death, the impact of an abnormal scan was strongest in
patients with low and moderate comorbidity.
An important study strength was access to a study
population in a setting of a universal free tax-supported
health care system. All Danish citizens have universal and
free access to general practitioners and hospitals, which
minimizes selection bias. Another study strength is com-
plete follow-up of all patients until the date of an outcome,
emigration, or end of follow-up.11 Information about the
SPECT MPI scan result was obtained before the informa-
tion on the outcomes. Furthermore, recorded diagnoses in
the DNPR are likely to be independent of the SPECT MPI
scan result. Any potential misclassification therefore
would be non-differential and cannot explain the increased
aHRs for MI and all-cause death.
We cannot entirely rule out that some patients with a
SPECT MPI scan in the study period were not registered in
the AUH-MPI Database. However, we assume that the asso-
ciation between SPECT MPI and outcomes among unregis-
tered patients would not differ from those among registered
patients. This should, therefore, not have influenced our
results.
The positive predictive values ofMI diagnoses and comor-
bidities included in the CCI have been reported to be high in
the DNPR; 97% for first-time MI,15 98% for CCI
comorbidities,16 and 88% for an inpatient diagnosis of recur-
rent MI.15 Mortality data from the Danish Civil Personal
Registration System are complete.10 We controlled for other
potential predictors (sex, age, and comorbidity level).
However, it is possible that other unmeasured variables, such
Table 2 Risk and hazard ratio of MI and all-cause death within 5 years following a normal versus abnormal scan, overall and according
to comorbidity level
Outcome Scan result No. of events Risk % (95% CI) Risk difference % (95% CI) Hazard ratio (95% CI)
Unadjusted Adjusted*
Overall
MI Normal 41 11.7 (8.5 – 15.5) 6.6 (2.1 – 11.1) 1 (reference) 1 (reference)
Abnormal 149 18.3 (15.7 – 21.0) 1.64 (1.16 – 2.31) 1.56 (1.09 – 2.21)
All-cause death Normal 27 8.0 (5.5 – 11.5) 5.2 (1.4 – 8.9) 1 (reference) 1 (reference)
Abnormal 104 13.2 (11.0 – 15.7) 1.66 (1.09 – 2.54) 1.39 (0.90 – 2.14)
Low comorbidity (0 points)
MI Normal 24 12.6 (8.1 – 18.1) 4.5 (−1.9 – 10.9) 1 (reference) 1 (reference)
Abnormal 62 17.1 (13.4 – 21.2) 1.41 (0.88 – 2.25) 1.33 (0.82 – 2.15)
All-cause death Normal 4 2.1 (0.8 – 5.4) 3.7 (0.5 – 6.8) 1 (reference) 1 (reference)
Abnormal 20 5.7 (3.7 – 8.8) 2.64 (0.90 – 7.72) 2.33 (0.79 – 6.84)
Moderate comorbidity (1 point)
MI Normal 10 12.0 (6.1 – 20.0) 4.6 (−4.2 – 13.3) 1 (reference) 1 (reference)
Abnormal 35 16.5 (11.9 – 21.8) 1.45 (0.72 – 2.93) 1.39 (0.68 – 2.83)
All-cause death Normal 4 5.2 (2.0 – 13.5) 5.1 (−1.5 – 11.6) 1 (reference) 1 (reference)
Abnormal 21 10.3 (6.8 – 15.4) 2.04 (0.70 – 5.96) 2.05 (0.69 – 6.06)
Severe comorbidity (≥2 points)
MI Normal 7 9.0 (4.0 – 16.7) 12.6 (3.8 – 21.4) 1 (reference) 1 (reference)
Abnormal 52 21.6 (16.7 – 27.1) 2.48 (1.13 – 5.45) 2.53 (1.14 – 5.62)
All-cause death Normal 19 25.9 (17.3 – 37.7) 0.8 (−10.9 – 12.4) 1 (reference) 1 (reference)
Abnormal 63 26.6 (21.5 – 32.8) 1.03 (0.62 – 1.72) 1.07 (0.64 – 1.80)
Note: Included are patients with a first-time MI within 5 years before the scan. *Adjusted for sex, age, and comorbidity level in the overall analyses, and sex and age in the
analyses stratified on comorbidity level.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
Dovepress Schelde et al
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Table 3 30-day, 31−365-day, and 1−5-year risk of MI and all-cause death following a normal versus abnormal scan
Time intervals Scan result No. of events Risk % (95% CI) Risk difference % (95% CI)
0−30 days
MI Normal 7 1.7 (0.6 – 3.6) −0.1 (−1.8 – 1.6)
Abnormal 14 1.6 (0.9 – 2.6)
All-cause death Normal 1 0.3 (0.0 – 1.9) −0.2 (−0.8 – 0.4)
Abnormal 1 0.1 (0.0 – 0.9)
31−365 days
MI Normal 15 4.0 (2.2 – 6.5) 3.3 (0.5 – 6.1)
Abnormal 60 7.2 (5.6 – 9.2)
All-cause death Normal 6 1.7 (0.8 – 3.7) 0.9 (−0.8 – 2.6)
Abnormal 21 2.5 (1.7 – 3.9)
1−5 years
MI Normal 19 6.5 (4.0 – 9.7) 4.1 (0.3 – 7.9)
Abnormal 75 10.6 (8.4 – 13.0)
All-cause death Normal 20 6.2 (4.0 – 9.5) 4.6 (1.1 – 8.0)
Abnormal 82 10.8 (8.8 – 13.2)
Note: Included are patients with a first-time MI within 5 years before the scan.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
Table 4 Risk and hazard ratio of MI registered during an acute admission within 5 years following a normal versus abnormal scan
Outcome Scan result No. of events Risk % (95% CI) Hazard ratio (95% CI)
Unadjusted Adjusted*
MI Normal 25 7.0 (4.6 – 10.2) 1 (reference) 1 (reference)
Abnormal 87 10.8 (8.8 – 13.1) 1.54 (0.98 – 2.40) 1.35 (0.86 – 2.12)
Note: Included are patients with a first-time MI within 5 years before the scan. *Adjusted for sex, age, and comorbidity level.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
Table 5 Risk and hazard ratio of MI and all-cause death within 5 years following a normal scan, a reversible defect, a fixed defect, and a
combined defect. Included are patients with a first-time MI within 5 years before the scan
Outcome Scan result No. of events Risk % (95% CI) Hazard ratio (95% CI)
Unadjusted Adjusted*
MI Normal 41 11.7 (8.5 – 15.5) 1 (reference) 1 (reference)
Reversible defect 21 14.1 (9.1 – 20.2) 1.25 (0.74 – 2.11) 1.22 (0.72 – 2.07)
Fixed defect 74 18.4 (14.7 – 22.4) 1.67 (1.14 – 2.44) 1.58 (1.07 – 2.33)
Combined defect 54 20.1 (15.5 – 25.1) 1.81 (1.21 – 2.72) 1.72 (1.14 – 2.61)
All-cause death Normal 27 8.0 (5.5 – 11.5) 1 (reference) 1 (reference)
Reversible defect 14 9.7 (5.9 – 15.9) 1.21 (0.64 – 2.31) 0.97 (0.51 – 1.85)
Fixed defect 49 12.6 (9.7 – 16.3) 1.61 (1.00 – 2.57) 1.41 (0.87 – 2.27)
Combined defect 41 15.9 (11.9 – 21.0) 2.00 (1.23 – 3.25) 1.61 (0.99 – 2.64)
Note: *Adjusted for sex, age, and comorbidity level.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
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as smoking, hypertension, and obesity, influenced the results.
Nevertheless, our primary aim was to assess the predictive
ability of SPECT MPI, rather than to examine a possibly
causal relation, in which confounding would have been an
issue.
Our study was of limited size. Thus, some of our
estimates were imprecise and with broad CIs, and we
cannot rule out that some of our findings are due to
chance. Finally, as we only included MI patients with a
SPECT MPI scan, we cannot generalize our findings to MI
patients without a SPECT MPI scan.
To our knowledge, no other studies have examined the
risk of MI and all-cause death as separate outcomes fol-
lowing an abnormal versus normal SPECT MPI scan in
MI patients, but previous studies have examined the risk of
MI or death as combined endpoints after MI following
SPECT.17,18 A study by Jain et al17 examined the risk of
death or reinfarction following dipyridamole thallium test-
ing 3 to 21 days after acute MI with a median follow-up of
18 months in 73 patients aged 65 years and older (mean
age 75 years). The authors reported that reversible ische-
mia was a predictor of death or reinfarction, with a relative
risk of 2.51 (95% CI: 1.05–5.96). Stratmann et al18 exam-
ined the risk of late cardiac events (non-fatal MI or cardiac
death) in 133 men hospitalized with an acute MI who had
technetium-99m sestamibi SPECT before hospital dis-
charge. The mean time to a cardiac event after testing
was 19 months, and in those patients without an event,
follow-up was 39 months. The study found that an isolated
fixed defect was a predictor of increased risk for late
cardiac events (relative risk of 2.1; 95% CI: 1.1–4.3).
These above-mentioned studies used combined end-
points. Therefore, their results are not completely compar-
able with our study’s results.
The impact of comorbidity level on risk of MI and all-
cause death following a normal versus abnormal SPECTMPI
scan has to our knowledge not previously been investigated in
patients with MI. Rather, earlier studies examined the risk of
adverse events following a normal versus abnormal SPECT
MPI in patients with selected chronic conditions, including
diabetes, obesity, and end-stage renal disease.19–21 These stu-
dies looked at specific chronic conditions rather than different
comorbidity levels, and did not restrict their study population
to previous MI patients. Their results are therefore not com-
parable with ours.
Conclusion
In conclusion, comorbidity level may modify the 5-
year risk prediction of an abnormal SPECT MPI scan
in patients with previous MI. The impact of an abnor-
mal scan was strongest for MI in patients with severe
comorbidity, and for all-cause death in patients with
low and moderate comorbidity. When SPECT MPI is
used as a prognostic tool, the difference in its predic-
tive value across comorbidity levels should be
considered.
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Figure 1 Estimated cumulative incidence of all-cause mortality risk among patients with normal and abnormal scans.
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Supplementary materials
Table S1 Diagnosis codes according to the International Classification of Diseases, 8th (ICD-8) and 10th revision (ICD-10)
Disease Weight ICD-8 codes ICD-10 codes
Myocardial infarction 1 410 I21, I22, I23
Congestive heart failure 1 427.09, 427.10, 427.11, 427.19, 428.99, 782.49 I50, I11.0, I13.0, I13.2
Peripheral vascular disease 1 440–445 I70–I74, I77
Cerebrovascular disease 1 430–438 I60–I69, G45, G46
Dementia 1 290.09–290.19, 293.09 F00–F03, F05.1, G30
Chronic pulmonary disease 1 490–493, 515–518 J40–J47, J60–J67, J68.4, J70.1, J70.3, J84.1, J92.0,
J96.1, J98.2, J98.3
Connective tissue disease 1 712, 716, 734, 446, 135.99 M05, M06, M08, M09, M30–M36, D86
Ulcer disease 1 530.91, 530.98, 531–534 K22.1, K25–K28
Mild liver disease 1 571, 573.01, 573.04 B18, K70.0–K70.3, K70.9, K71, K73, K74, K76.0
Diabetes I and II 1 249.00, 249.06, 249.07, 249.09, 250.00, 250.06,
250.07, 250.09
E10.0, E10.1, E10.9, E11.0, E11.1, E11.9
Hemiplegia 2 334 G81, G82
Moderate to severe kidney
disease
2 403, 404, 580–584, 590.09, 593.19, 753.10–
753.19, 792
I12, I13, N00–N05, N07, N11, N14, N17–N19,
Q61
Diabetes with end organ
damage
2 249.01–249.05, 249.08, 250.01–250.05, 250.08 E10.2–E10.8, E11.2–E11.8
Any tumor 2 140–194 C00–C75
Leukemia 2 204–207 C91–C95
Lymphoma 2 200–203, 275.59 C81–C85, C88, C90, C96
Moderate to severe liver
disease
3 070.00, 070.02, 070.04, 070.06, 070.08, 573.00,
456.00–456.09
B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Metastatic solid tumor 6 195–199 C76–C80
AIDS 6 079.83 B21–B24
Table S2 Diagnosis codes for myocardial infarction according to
the International Classification of Diseases, 8th (ICD-8) and 10th
(ICD-10) revision
Myocardial infarction ICD-8 codes ICD-10 codes
Prior to the scan 410 I21, I22, I23
Outcome 410 I21
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Table S4 Risk and hazard ratio of MI and all-cause death within 5 years following a normal versus abnormal scan.
Hazard ratio (95% CI)
Outcome Scan result No. of events Risk % (95% CI) Risk difference % (95% CI) Unadjusted Adjusted*
MI Normal 19 11.4 (6.8 – 17.2) 5.6 (−1.1 – 12.3) 1 (reference) 1 (reference)
Abnormal 64 17.0 (13.4 – 21.0) 1.62 (0.97 – 2.70) 1.57 (0.93 – 2.65)
All-cause death Normal 13 8.2 (4.8 – 13.7) 6.6 (0.9 – 12.2) 1 (reference) 1 (reference)
Abnormal 54 14.8 (11.5 – 18.8) 1.88 (1.03 – 3.45) 1.56 (0.84 – 2.89)
Note: Included are patients with a first-time MI >1−5 years before the scan. *Adjusted for sex, age, and comorbidity level.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
Table S3 Risk and hazard ratio of MI and all-cause death within 5 years following a normal versus abnormal scan
Hazard ratio (95% CI)
Outcome Scan result No. of events Risk % (95% CI) Risk difference % (95% CI) Unadjusted Adjusted*
MI Normal 22 11.4 (7.2 – 16.7) 8.1 (1.9 – 14.2) 1 (reference) 1 (reference)
Abnormal 85 19.4 (15.9 – 23.3) 1.64 (1.03 – 2.62) 1.53 (0.95 – 2.47)
All-cause death Normal 14 7.9 (4.7 – 13.0) 3.9 (−1.1 – 8.9) 1 (reference) 1 (reference)
Abnormal 50 11.8 (9.1 – 15.3) 1.48 (0.82 – 2.67) 1.19 (0.65 – 2.17)
Note: Included are patients with a first-time MI 0−1 year before the scan. *Adjusted for sex, age, and comorbidity level.
Abbreviations: CI, confidence interval; MI, myocardial infarction.
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